228 related articles for article (PubMed ID: 24629895)
1. Risk of major bleeding and the standard doses of dabigatran.
Antoniazzi S; Berdaï D; Conti V; Clementi E; Salvo F
Eur J Intern Med; 2014 Jul; 25(6):e73-5. PubMed ID: 24629895
[No Abstract] [Full Text] [Related]
2. Increased risk of myocardial infarction with dabigatran: fact or fiction?
Giglio AF; Basile E; Santangeli P; Di Biase L; Trotta F; Natale A
J Cardiovasc Med (Hagerstown); 2014 Jan; 15(1):19-26. PubMed ID: 24492353
[TBL] [Abstract][Full Text] [Related]
3. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
4. Pitfalls of the interpretation of myocardial infarction data in patients on dabigatran treatment.
Pontillo D; Patruno N
J Cardiovasc Med (Hagerstown); 2015 Feb; 16(2):142. PubMed ID: 25539158
[No Abstract] [Full Text] [Related]
5. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
[TBL] [Abstract][Full Text] [Related]
6. [Dabigatran in prevention of stroke in atrial fibrillation: three years of clinical application].
Zotova IV; Zateĭshchikov DA
Kardiologiia; 2014; 54(2):79-85. PubMed ID: 24888206
[No Abstract] [Full Text] [Related]
7. Dabigatran for stroke prevention in all patients with atrial fibrillation?
Hunchuck JE; Lake JD
Pharmacotherapy; 2011 Aug; 31(8):725-8. PubMed ID: 21923597
[No Abstract] [Full Text] [Related]
8. [Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].
Lewalter T
MMW Fortschr Med; 2012 Mar; 154(5):50-2, 54. PubMed ID: 22624265
[No Abstract] [Full Text] [Related]
9. Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Majeed A; Hwang HG; Connolly SJ; Eikelboom JW; Ezekowitz MD; Wallentin L; Brueckmann M; Fraessdorf M; Yusuf S; Schulman S
Circulation; 2013 Nov; 128(21):2325-32. PubMed ID: 24081972
[TBL] [Abstract][Full Text] [Related]
10. Place of dabigatran in contemporary pharmacotherapy.
Gums JG
Pharmacotherapy; 2011 Apr; 31(4):335-7. PubMed ID: 21449622
[No Abstract] [Full Text] [Related]
11. The importance of postapproval data for dabigatran.
Redberg RF
JAMA Intern Med; 2015 Jan; 175(1):25. PubMed ID: 25365377
[No Abstract] [Full Text] [Related]
12. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
[TBL] [Abstract][Full Text] [Related]
13. Dabigatran for stroke prevention in atrial fibrillation.
Hohnloser SH; Diener HC
Hamostaseologie; 2012; 32(3):216-20. PubMed ID: 22739760
[TBL] [Abstract][Full Text] [Related]
14. Application of the RELY study to lifetime risks of atrial fibrillation: implications for spontaneous intracranial hemorrhage.
Parry PV; Engh JA
Neurosurgery; 2012 Feb; 70(2):N10-1. PubMed ID: 22251978
[No Abstract] [Full Text] [Related]
15. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Connolly SJ; Wallentin L; Ezekowitz MD; Eikelboom J; Oldgren J; Reilly PA; Brueckmann M; Pogue J; Alings M; Amerena JV; Avezum A; Baumgartner I; Budaj AJ; Chen JH; Dans AL; Darius H; Di Pasquale G; Ferreira J; Flaker GC; Flather MD; Franzosi MG; Golitsyn SP; Halon DA; Heidbuchel H; Hohnloser SH; Huber K; Jansky P; Kamensky G; Keltai M; Kim SS; Lau CP; Le Heuzey JY; Lewis BS; Liu L; Nanas J; Omar R; Pais P; Pedersen KE; Piegas LS; Raev D; Smith PJ; Talajic M; Tan RS; Tanomsup S; Toivonen L; Vinereanu D; Xavier D; Zhu J; Wang SQ; Duffy CO; Themeles E; Yusuf S
Circulation; 2013 Jul; 128(3):237-43. PubMed ID: 23770747
[TBL] [Abstract][Full Text] [Related]
16. Patient Characteristics and Risk of Bleeding With Dabigatran in Atrial Fibrillation.
Henriksen DP; Hansen MR; Damkier P
JAMA Intern Med; 2015 Jul; 175(7):1245. PubMed ID: 26146921
[No Abstract] [Full Text] [Related]
17. Dosage of Dabigatran as a Risk Factor for Bleeding in Atrial Fibrillation.
Liu S; Kim CO; Lucyk SN
JAMA Intern Med; 2015 Jul; 175(7):1244-5. PubMed ID: 26146920
[No Abstract] [Full Text] [Related]
18. The Role of Selection in the Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation.
Klil-Drori A; Azoulay L
JAMA Intern Med; 2015 Jul; 175(7):1243-4. PubMed ID: 26146918
[No Abstract] [Full Text] [Related]
19. Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice.
Kawabata M; Yokoyama Y; Sasano T; Hachiya H; Tanaka Y; Yagishita A; Sugiyama K; Nakamura T; Suzuki M; Isobe M; Hirao K
J Cardiol; 2013 Aug; 62(2):121-6. PubMed ID: 23680005
[TBL] [Abstract][Full Text] [Related]
20. [Dabigatran and risk of bleeding].
Hasler S
Praxis (Bern 1994); 2015 Jan; 104(3):157-8. PubMed ID: 25626386
[No Abstract] [Full Text] [Related]
[Next] [New Search]
